Skip to main content
SpringerLink
Log in

Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi

  • Discussion
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Garatinni, L., Ghislandi, S.: Should we really worry about “launch delays” of new drugs in OECD countries?” Eur. J. Health Econ. 8, 1–3 (2007)

    Article  Google Scholar 

  2. Danzon, P., Wang, M., Wang, L.: The impact of price regulation on the launch delay of new drugs—evidence from twenty five major markets in the 1990s. Health Econ. 14, 269–295 (2005)

    Article  Google Scholar 

  3. Cohen, J., Faden, L., Predaris, S., Young, B.: Patient access to pharmaceuticals: an international comparison. Eur. J. Health Econ. (2007) http://dx.doi.org/10.1007/s10198-006-0028-z

  4. Devlin, N., Parkin, D.: Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 13(5), 437–452 (2004)

    Article  Google Scholar 

  5. Jonsson, B., Wilking, N.: A pan-European comparison of patient access to cancer medications. See http://ki.se/content/1/c4/33/52/Cancer_Report.pdf. Accessed 11 March (2007)

Download references

Author information

Authors and Affiliations

  1. Tufts Center for the Study of Drug Development, Tufts University, 192 South Street, Boston, MA, 02111, USA

    Joshua Cohen

  2. Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands

    Joshua Cohen

Authors
  1. Joshua Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joshua Cohen.

Additional information

An author’s reply to this comment is available at doi:10.1007/s10198-007-0056-3. The original article is available at doi:10.1007/s10198-006-0022-5.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, J. Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi. Eur J Health Econ 8, 169–170 (2007). https://doi.org/10.1007/s10198-007-0055-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-007-0055-4

Keywords

Search

Navigation